Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Source:http://linkedlifedata.com/resource/pubmed/id/20404738

Download in:

View as

General Info

PMID
20404738